All posts
-
Anglo sees growth in refocused portfolio earnings despite reporting wider loss of $3.7bn
Worldwide varied miner Anglo American is beginning to see hidden profits prior to rate of interest, tax obligations, devaluation and amortisation (Ebitda) gains from its streamline…
-
ALK aims for double-digit growth in 2026
For the entire of 2025, ALK accomplished earnings development of 15% and overall earnings of DKK 6.3 bn (USD 993m).
-
ALK’s chief scientific officer resigns
Henriette Mersebach is leaving her placement as EVP of R&D at ALK by shared arrangement.
-
Zealand Pharma nominates UCB veteran for its board of directors
Iris Loew-Friedrich belonged to UCB’s exec board from 2008 to 2024.
-
Genmab CEO points to Epkinly data as main event of the year
First-line therapy will possibly open a substantial market. Epkinly is currently accepted for DLBCL individuals that have actually gotten 2 or even more therapies.
-
Zealand Pharma expects new research center in Boston commisioned by summer
The proving ground intends to increase the biotech business’s medicine r & d.
-
Money earmarked for new Zealand Pharma partnerships – expects more deals signed soon
The coming duration will certainly see even more collaborations for the Danish biotech business and a concentrated initiative on automation and AI.
-
Zealand Pharma explores opportunities in weight-loss pill market
Novo Nordisk and Eli Lilly are concentrating on tablet computer variations of GLP-1 medicines. Zealand Pharma is taking a various strategy with amylin.
-
Leo Pharma expects margin shortfall, owners maintain 2026 IPO ambitions
Leo Pharma’s owners remain optimistic about a potential IPO in 2026, despite the company not expecting to reach its target of a minimum 20% earnings margin this year.
-
Recording webinar ‘From strategy to working capital optimisation’
Organisations yap regarding approach, development and consumer assurance. However inevitably, that approach is mirrored in stock and as a result in functioning funding on the annua…
